Skip to main content
. 2021 Feb 16;10:610787. doi: 10.3389/fonc.2020.610787

Figure 3.

Figure 3

Sensitivity analysis of overall survival (A), progression-free survival (B), distance metastasis-free survival (C), and locoregional recurrence-free survival (D) between IC+CCRT and CCRT based on EBV-DNA ≥4000 copies/ml.